David Dobnik
From 2016, David Dobnik has been closely working with companies in the field of gene therapy (such as AveXis [now Novartis Gene Therapies]) to develop and apply methods for precise quantification of viral vectors (e.g. dPCR), observation of viral particles (electron microscopy), and for identification and quantification of impurities (e.g. nucleic acids by high-throughput sequencing [HTS/NGS] or PCR-based methods). David has been leading the development and tech-transfer projects for pharmaceutical companies focused on the field of gene therapy, helping their process development efforts with characterizations of viral vectors. Lately, most of his work  has been focused on new approaches for genome integrity evaluation.

No Digital PCR Festival would be complete without exploring the use of digital PCR in biopharmaceutical manufacturing. Discover how scientists apply dPCR in cell and gene therapies where precision and sensitivity are of highest importance.

  • Opening remarks from QIAGEN
  • PCR in Biopharma - Past, Present, and the Future
    Speaker: Prof Dr. Mikael Kubista, Institute of Biotechnology, Czech Academy of Sciences, Czech Republic
  • Digital PCR Empowers Liquid Biopsy for Comprehensive Solid Tumor Management: Integrating Circulating Tumor Cells and Extracellular Vesicles
    Speaker: Prof Dr. Hsian-Rong Tseng, David Geffen School of Medicine at UCLA, USA
  • Multiplex dPCR offers quantitative viral vector genome integrity evaluation
    Speaker: Assist. Prof. Dr. David Dobnik, Niba Labs d.o.o. , Slovenia
  • Digital PCR Applications for Gene Therapy Products Including AAV Quantitation
    Speaker: Mr. Stuart Nelson, Eli Lilly and Company, USA
  • Quantifying AAV vector genome titer in process  ̶  intermediate samples by digital PCR and digital droplet PCR (d/dPCR)
    Speaker: Mr. Chieme Kennedy Okechukwu, National Resilience, USA
  • Closing remarks from QIAGEN
Dr. Mikael Kubista and 4 other experts